<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04855266</url>
  </required_header>
  <id_info>
    <org_study_id>21-000488</org_study_id>
    <nct_id>NCT04855266</nct_id>
  </id_info>
  <brief_title>Iron Sucrose in Patients With Iron Deficiency and POTS</brief_title>
  <official_title>A Randomized, Controlled, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy of Intravenous Iron Sucrose in Patients With Non-anemic Iron Deficiency and Postural Orthostatic Tachycardia Syndrome (POTS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate whether the treatment of non-anemic iron deficiency with&#xD;
      intravenous iron sucrose will result in decreased symptom reporting and improved&#xD;
      cardiovascular indices in patients with Postural Orthostatic Tachycardia syndrome (POTS).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in autonomic dysfunction symptoms</measure>
    <time_frame>Baseline, 7 days, 6 months</time_frame>
    <description>Measured using the self-reported Composite Autonomic Symptom Score (COMPASS) questionnaire that asks 31 questions regarding symptoms of autonomic dysfunction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in postural heart rate increase</measure>
    <time_frame>Baseline, 7 days</time_frame>
    <description>Heart rate change during tilt table test measured in beats per minute</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Iron-deficiency</condition>
  <condition>Postural Orthostatic Tachycardia Syndrome</condition>
  <arm_group>
    <arm_group_label>Iron Sucrose Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive intravenous iron sucrose during a tilt table test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive intravenous placebo during a tilt table test</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sucrose</intervention_name>
    <description>5 mg/kg of intravenous iron sucrose (maximum dose of 200 mg). Iron sucrose will be diluted</description>
    <arm_group_label>Iron Sucrose Group</arm_group_label>
    <other_name>Venofer</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline (NaCl 0.9%) 5 mL/kg (maximum volume 210 mL)</description>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Tilt Table Test</intervention_name>
    <description>A table that adjusts the body position from horizontal to vertical to simulate standing up. Heart rate and blood pressure are monitored throughout the test.</description>
    <arm_group_label>Iron Sucrose Group</arm_group_label>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients (age 12 to years and older) with chronic (&gt;3 months) symptoms of orthostatic&#xD;
             intolerance, including but not limited to lightheadedness, syncope, headache, fatigue,&#xD;
             weakness, sweating, nausea and heart palpitations.&#xD;
&#xD;
          -  Symptomatic orthostatic heart rate increment ≥30 bpm if &gt;19 years old or ≥40 bpm if&#xD;
             &lt;19 years old during a 10 minute 70 degree head up tilt study&#xD;
&#xD;
          -  Presence of non-anemic iron deficiency, defined as serum ferritin levels &lt;20 ug/L with&#xD;
             hemoglobin no less than 1 gm/dL below the normal reference range as defined for age&#xD;
             and gender&#xD;
&#xD;
          -  Consent obtained from responsible guardian AND from subjects, 12-17 years of age&#xD;
&#xD;
          -  Consent obtained for subjects 18 years of age and older&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Orthostatic hypotension (decrease of systolic BP&gt;30 mmHg and/or diastolic BP&gt;15mmHg&#xD;
             within 3 minutes of 70 degree head up tilt study)&#xD;
&#xD;
          -  Pregnant or lactating females&#xD;
&#xD;
          -  The presence of failure of other organ systems or systemic illness that can affect&#xD;
             autonomic function&#xD;
&#xD;
          -  Concomitant therapy with anticholinergic, alpha-adrenergic antagonists,&#xD;
             beta-adrenergic antagonists or other medications which could interfere with autonomic&#xD;
             testing. Patients may participate if the potentially interfering medication is held&#xD;
             for five half-lives prior to the study&#xD;
&#xD;
          -  Laboratory evidence of anemia or iron overload&#xD;
&#xD;
          -  Personal history of hematochromatosis or first degree relative with hematochromatosis&#xD;
&#xD;
          -  Known sensitivity to Venofer® (iron sucrose injection, USP) or other intravenous iron&#xD;
             preparation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kamal Shouman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tonette Gehrking</last_name>
      <phone>507-284-0336</phone>
      <email>adc.research@mayo.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 19, 2021</study_first_submitted>
  <study_first_submitted_qc>April 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2021</study_first_posted>
  <last_update_submitted>July 6, 2021</last_update_submitted>
  <last_update_submitted_qc>July 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Kamal Shouman</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Postural Orthostatic Tachycardia Syndrome</mesh_term>
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ferric Oxide, Saccharated</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

